Alberto Palazzuoli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5380223/publications.pdf

Version: 2024-02-01

136 papers	4,139 citations	172207 29 h-index	133063 59 g-index
138 all docs	138 docs citations	138 times ranked	5583 citing authors

#	Article	IF	Citations
1	Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions. Heart Failure Reviews, 2023, 28, 683-695.	1.7	3
2	Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants. Heart Failure Reviews, 2023, 28, 597-606.	1.7	29
3	Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence. Heart Failure Reviews, 2023, 28, 585-596.	1.7	11
4	Noncardiac comorbidity clustering in heart failure: an overlooked aspect with potential therapeutic door. Heart Failure Reviews, 2022, 27, 767-778.	1.7	6
5	Direct oral anticoagulants across the heart failure spectrum: the precision medicine era. Heart Failure Reviews, 2022, 27, 135-145.	1.7	2
6	Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study. International Journal of Cardiology, 2022, 350, 62-68.	0.8	13
7	Usefulness of Combined Renin-Angiotensin System Inhibitors and Diuretic Treatment In Patients Hospitalized with COVID-19. American Journal of Cardiology, 2022, , .	0.7	3
8	An update on diabetes spectrum in heart failure: current evidence and potential therapeutic applications. Heart Failure Reviews, 2022, , 1.	1.7	1
9	Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan. ESC Heart Failure, 2022, 9, 1107-1117.	1.4	12
10	Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis. Canadian Journal of Physiology and Pharmacology, 2022, 100, 93-106.	0.7	11
11	Different Renal Function Patterns in Patients With Acute Heart Failure: Relationship With Outcome and Congestion. Frontiers in Cardiovascular Medicine, 2022, 9, 779828.	1.1	0
12	Clinical, Laboratory and Lung Ultrasound Assessment of Congestion in Patients with Acute Heart Failure. Journal of Clinical Medicine, 2022, 11, 1642.	1.0	10
13	The Treatment of Heart Failure in Patients with Chronic Kidney Disease: Doubts and New Developments from the Last ESC Guidelines. Journal of Clinical Medicine, 2022, 11, 2243.	1.0	6
14	Structural and Hemodynamic Changes of the Right Ventricle in PH-HFpEF. International Journal of Molecular Sciences, 2022, 23, 4554.	1.8	4
15	Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology. European Journal of Internal Medicine, 2022, 102, 8-16.	1.0	10
16	Long-term outcome of myocardial scarring and deformation with cardiovascular magnetic resonance in out of hospital cardiac arrest survivors. European Heart Journal Cardiovascular Imaging, 2021, 22, 1149-1156.	0.5	7
17	Association between right-sided cardiac function and ultrasound-based pulmonary congestion on acutely decompensated heart failure: findings from a pooled analysis of four cohort studies. Clinical Research in Cardiology, 2021, 110, 1181-1192.	1.5	26
18	Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. American Journal of Medicine, 2021, 134, 16-22.	0.6	105

#	Article	IF	Citations
19	Cardiovascular Magnetic Resonance of Myocardial Fibrosis, Edema, and Infiltrates in Heart Failure. Heart Failure Clinics, 2021, 17, 77-84.	1.0	5
20	Screening, detection, and management of heart failure in the SARS-CoV2 (COVID-19) pandemic. Heart Failure Reviews, 2021, 26, 973-979.	1.7	4
21	The relevance of specific heart failure outpatient programs in the COVID era: an appropriate model for every disease. Reviews in Cardiovascular Medicine, 2021, 22, 677.	0.5	2
22	Thromboembolic Complications in Covid-19: From Clinical Scenario to Laboratory Evidence. Life, 2021, 11, 395.	1.1	2
23	Noncardiovascular comorbidities in patients with heart failure and their impact on prognosis. Kardiologia Polska, 2021, 79, 493-502.	0.3	3
24	Are HFpEF and HFmrEF So Different? The Need to Understand Distinct Phenotypes. Frontiers in Cardiovascular Medicine, 2021, 8, 676658.	1.1	9
25	Nomenclature for Kidney Function from KDIGO: Shortcomings of Terminology Oversimplification. CardioRenal Medicine, 2021, 11, 1-4.	0.7	2
26	Recent advances in pharmacological treatment of heart failure. European Journal of Clinical Investigation, 2021, 51, e13624.	1.7	19
27	Pulmonary Congestion Assessment in Heart Failure: Traditional and New Tools. Diagnostics, 2021, 11, 1306.	1.3	8
28	Cardiac congestion assessed by natriuretic peptides oversimplifies the definition and treatment of heart failure. ESC Heart Failure, 2021, 8, 3453-3457.	1.4	4
29	Current gaps in HFpEF trials: Time to reconsider patients' selection and to target phenotypes. Progress in Cardiovascular Diseases, 2021, 67, 89-97.	1.6	12
30	Impact of reninâ€“angiotensinâ€“aldosterone system inhibitor continuation on outcomes for patients with severe coronavirus disease 2019 manifestations. Journal of Hypertension, 2021, 39, 1725-1726.	0.3	2
31	Effects of Metolazone Administration on Congestion, Diuretic Response and Renal Function in Patients with Advanced Heart Failure. Journal of Clinical Medicine, 2021, 10, 4207.	1.0	9
32	Congestion occurrence and evaluation in acute heart failure scenario: authorâ€™s replay to the letter. Heart Failure Reviews, 2021, 26, 733-733.	1.7	0
33	Congestion occurrence and evaluation in acute heart failure scenario: time to reconsider different pathways of volume overload. Heart Failure Reviews, 2020, 25, 119-131.	1.7	27
34	Unusual cardiac mass presenting as humeral artery embolisation. Journal of Clinical Pathology, 2020, 73, 57-57.	1.0	1
35	Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure. European Journal of Internal Medicine, 2020, 71, 23-31.	1.0	29
36	The role of the kidney in acute and chronic heart failure. Heart Failure Reviews, 2020, 25, 107-118.	1.7	24

#	Article	IF	Citations
37	Myocardial phenotypes and dysfunction in HFpEF and HFrEF assessed by echocardiography and cardiac magnetic resonance. Heart Failure Reviews, 2020, 25, 75-84.	1.7	7
38	Hyperuricemia: a novel old disorderâ€"relationship and potential mechanisms in heart failure. Heart Failure Reviews, 2020, 25, 43-51.	1.7	28
39	Inpatient Mortality According to Level of Respiratory Support Received for Severe Acute Respiratory Syndrome Coronavirus 2 (Coronavirus Disease 2019) Infection: A Prospective Multicenter Study. , 2020, 2, e0220.		2
40	Antecedent Administration of Angiotensinâ€Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVIDâ€19 Syndrome. Journal of the American Heart Association, 2020, 9, e017364.	1.6	29
41	Mortality Risk Assessment Using CHA(2)DS(2)-VASc Scores in Patients Hospitalized With Coronavirus Disease 2019 Infection. American Journal of Cardiology, 2020, 137, 111-117.	0.7	18
42	In-hospital Routes of Acute Heart Failure Admissions During COVID-19. Frontiers in Cardiovascular Medicine, 2020, 7, 581458.	1.1	1
43	Glucose Metabolism in the Kidney: Neurohormonal Activation and Heart Failure Development. Journal of the American Heart Association, 2020, 9, e018889.	1.6	39
44	Pulmonary arterial hypertension and heart failure with preserved ejection fraction: are they so discordant?. Cardiovascular Diagnosis and Therapy, 2020, 10, 534-545.	0.7	5
45	Reduction in heart failure hospitalization rate during coronavirus disease 19 pandemic outbreak. ESC Heart Failure, 2020, 7, 4182-4188.	1.4	28
46	Acute Coronary Syndromes and Covid-19: Exploring the Uncertainties. Journal of Clinical Medicine, 2020, 9, 1683.	1.0	82
47	Comprehensive heart failure assessment: A challenge to modify the course of heart failure. Author's reply. European Journal of Internal Medicine, 2020, 74, 125-126.	1.0	1
48	Prognostic Significance of an Early Echocardiographic Evaluation of Right Ventricular Dimension and Function in Acute Heart Failure. Journal of Cardiac Failure, 2020, 26, 813-820.	0.7	15
49	Ultrasound indices of congestion in patients with acute heart failure according to body mass index. Clinical Research in Cardiology, 2020, 109, 1423-1433.	1.5	14
50	Hypertension prevalence in human coronavirus disease: the role of ACE system in infection spread and severity. International Journal of Infectious Diseases, 2020, 95, 373-375.	1.5	15
51	Urgent need for individual mobile phone and institutional reporting of at home, hospitalized, and intensive care unit cases of SARS-CoV-2 (COVID-19) infection. Reviews in Cardiovascular Medicine, 2020, 21, 1.	0.5	24
52	Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy. International Journal of Molecular Sciences, 2019, 20, 3264.	1.8	93
53	The use of diuretics in heart failure with congestion: we can't judge a book by its cover. ESC Heart Failure, 2019, 6, 1222-1225.	1.4	4
54	Loop Diuretic Administration in Patients with Acute Heart Failure and Reduced Systolic Function: Effects of Different Intravenous Diuretic Doses and Diuretic Response Measurements. Journal of Clinical Medicine, 2019, 8, 1854.	1.0	5

#	Article	IF	Citations
55	Hyperuricemia in US Population with Heart Failure: Causal or Incidental Bystander?. CardioRenal Medicine, 2019, 9, 341-343.	0.7	3
56	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 1304-1317.	2.6	232
57	Combination of ST2 and B-type natriuretic peptide in diabetic patients with acute heart failure. Journal of Cardiovascular Medicine, 2019, 20, 81-90.	0.6	10
58	Early readmission for heart failure: An avoidable or ineluctable debacle?. International Journal of Cardiology, 2019, 277, 186-195.	0.8	15
59	The prognostic role of different renal function phenotypes in patients with acute heart failure. International Journal of Cardiology, 2019, 276, 198-203.	0.8	10
60	The EUROpean and Chinese cardiac and renal Remote Ischemic Preconditioning Study (EURO-CRIPS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.8	46
61	Sex-related differences in chronic heart failure. International Journal of Cardiology, 2018, 255, 145-151.	0.8	41
62	Clinical impact of oral antidiabetic medications in heart failure patients. Heart Failure Reviews, 2018, 23, 325-335.	1.7	10
63	The importance of integrated left atrial evaluation: From hypertension to heart failure with preserved ejection fraction. International Journal of Clinical Practice, 2018, 72, e13050.	0.8	18
64	Arterial hypertension and atrial fibrillation. Journal of Cardiovascular Medicine, 2018, 19, 51-61.	0.6	4
65	Combined use of lung ultrasound, B-type natriuretic peptide, and echocardiography for outcome prediction in patients with acute HFrEF and HFpEF. Clinical Research in Cardiology, 2018, 107, 586-596.	1.5	79
66	The need for evaluating right ventricular adaptation and ventriculoâ€“arterial coupling. European Journal of Heart Failure, 2018, 20, 943-944.	2.9	0
67	Heartâ€“Kidney Interactions in Cardiorenal Syndrome Type 1. Advances in Chronic Kidney Disease, 2018, 25, 408-417.	0.6	17
68	Right heart dysfunction. Journal of Cardiovascular Medicine, 2018, 19, 613-623.	0.6	10
69	Hyponatremia in Acute Heart Failure in Relation to Hematocrit Levels: Clinical Relevance and Prognostic Implication. CardioRenal Medicine, 2018, 8, 259-270.	0.7	7
70	Resistant hypertension: an overview. Minerva Cardiology and Angiology, 2018, 66, 337-348.	0.4	5
71	Different trajectories and significance of B-type natriuretic peptide, congestion and acute kidney injury in patients with heart failure. Internal and Emergency Medicine, 2017, 12, 593-603.	1.0	9
72	Rationale and study design of intravenous loop diuretic administration in acute heart failure: DIURâ€AHF. ESC Heart Failure, 2017, 4, 479-486.	1.4	20

#	Article	IF	Citations
73	Prevalence of Hyperuricemia in Patients With Acute Heart Failure With Either Reduced or Preserved Ejection Fraction. American Journal of Cardiology, 2017, 120, 1146-1150.	0.7	48
74	The paradox of transient worsening renal function in patients with acute heart failure. Journal of Cardiovascular Medicine, 2017, 18, 851-858.	0.6	11
75	Hyperuricemia and Cardiovascular Disease. Reviews in Cardiovascular Medicine, 2017, 18, 134-145.	0.5	0
76	The prognostic combined role of B-type natriuretic peptide, blood urea nitrogen and congestion signs persistence in patients with acute heart failure. Journal of Cardiovascular Medicine, 2016, 17, 818-827.	0.6	16
77	Prognostic Significance of Hyperuricemia in Patients With Acute Heart Failure. American Journal of Cardiology, 2016, 117, 1616-1621.	0.7	41
78	Different diuretic dose and response in acute decompensated heart failure: Clinical characteristics and prognostic significance. International Journal of Cardiology, 2016, 224, 213-219.	0.8	25
79	Additional value of Galectin-3 to BNP in acute heart failure patients with preserved ejection fraction. Clinica Chimica Acta, 2016, 457, 99-105.	0.5	26
80	Chronic kidney disease and worsening renal function in acute heart failure: different phenotypes with similar prognostic impact?. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 534-548.	0.4	28
81	Diagnostic utility of contemporary echo and BNP assessment in patients with acute heart failure during early hospitalization. European Journal of Internal Medicine, 2016, 30, 43-48.	1.0	7
82	Kidney disease in heart failure: the importance of novel biomarkers for type 1 cardio-renal syndrome detection. Internal and Emergency Medicine, 2015, 10, 543-554.	1.0	19
83	Role of BNP and echo measurement for pulmonary hypertension recognition in patients with interstitial lung disease: AnÂalgorithm application model. Respiratory Medicine, 2015, 109, 406-415.	1.3	27
84	Early detection of pulmonary arterial hypertension: do not forget the right ventricle. Nature Reviews Cardiology, 2015, 12, 134-134.	6.1	4
85	The impact of infarct size on regional and global left ventricular systolic function: a cardiac magnetic resonance imaging study. International Journal of Cardiovascular Imaging, 2015, 31, 1037-1044.	0.7	18
86	Comparison of Neutrophil Gelatinase-Associated Lipocalin Versus B-Type Natriuretic Peptide and Cystatin C to Predict Early Acute Kidney Injury and Outcome in Patients With Acute Heart Failure. American Journal of Cardiology, 2015, 116, 104-111.	0.7	44
87	Loop diuretics in acute heart failure: beyond the decongestive relief for the kidney. Critical Care, 2015, 19, 296.	2.5	44
88	Short and long-term effects of continuous versus intermittent loop diuretics treatment in acute heart failure with renal dysfunction. Internal and Emergency Medicine, 2015, 10, 41-49.	1.0	15
89	Combined BNP and Echocardiographic assessment in interstitial lung disease for pulmonary hypertension detection. International Journal of Cardiology, 2015, 178, 34-36.	0.8	4
90	Loop Diuretics Strategies in Acute Heart Failure: From Clinical Trials to Practical Application. Current Drug Targets, 2015, 16, 1246-1253.	1.0	3

#	Article	IF	Citations
91	Pulmonary hypertension: a correct diagnosis for a suitable therapy in scleroderma patients. Clinical and Experimental Rheumatology, 2015, 33, S182-9.	0.4	5
92	The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions. Therapeutics and Clinical Risk Management, 2014, 10, 641.	0.9	28
93	Cross-sectional study: CagAâ€“positiveHelicobacter pyloriinfection, acute coronary artery disease and systemic levels of B-type natriuretic peptide. Journal of Clinical Pathology, 2014, 67, 251-257.	1.0	36
94	Admission plasma neutrophil gelatinase associated lipocalin (NGAL) predicts worsening renal function during hospitalization and post discharge outcome in patients with acute heart failure. Acute Cardiac Care, 2014, 16, 93-101.	0.2	36
95	Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial. Critical Care, 2014, 18, R134.	2.5	53
96	Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin. Heart Failure Reviews, 2014, 19, 267-284.	1.7	35
97	Patients with Cardiorenal Syndrome Revealed Increased Neurohormonal Activity, Tubular and Myocardial Damage Compared to Heart Failure Patients with Preserved Renal Function. CardioRenal Medicine, 2014, 4, 257-268.	0.7	18
98	The potential role of natriuretic peptides in acute coronary syndrome stratification. Future Cardiology, 2013, 9, 297-300.	0.5	0
99	Natriuretic peptides in acute chest pain and acute coronary syndrome. Coronary Artery Disease, 2013, 24, 33-39.	0.3	3
100	The Role of Natriuretic Peptides for the Diagnosis of Left Ventricular Dysfunction. Scientific World Journal, The, 2013, 2013, 1-10.	0.8	10
101	B-type natriuretic peptide as an independent predictor of coronary disease extension in non-ST elevation coronary syndromes with preserved systolic function. European Journal of Preventive Cardiology, 2012, 19, 366-373.	0.8	9
102	Prevalence and non-invasive predictors of left main or three-vessel coronary disease: evidence from a collaborative international meta-analysis including 22â€ˆ740 patients. Heart, 2012, 98, 914-919.	1.2	72
103	Natriuretic peptides and NGAL in heart failure: Does a link exist?. Clinica Chimica Acta, 2012, 413, 1832-1838.	0.5	19
104	B-type natriuretic peptide levels predict extent and severity of coronary disease in non-ST elevation coronary syndromes and normal left ventricular systolic function. Regulatory Peptides, 2011, 167, 129-133.	1.9	9
105	Epidemiology and outcome of the cardio-renal syndrome. Heart Failure Reviews, 2011, 16, 531-542.	1.7	42
106	Anemia in Cardio-Renal Syndrome: clinical impact and pathophysiologic mechanisms. Heart Failure Reviews, 2011, 16, 603-607.	1.7	18
107	Laboratory parameters of cardiac and kidney dysfunction in cardio-renal syndromes. Heart Failure Reviews, 2011, 16, 545-551.	1.7	24
108	Cardio-renal syndrome: an entity cardiologists and nephrologists should be dealing with collegially. Heart Failure Reviews, 2011, 16, 503-508.	1.7	17

#	Article	IF	Citations
109	Anemia correction by erythropoietin reduces BNP levels, hospitalization rate, and NYHA class in patients with cardio-renal anemia syndrome. Clinical and Experimental Medicine, 2011, 11, 43-48.	1.9	20
110	Natriuretic peptides in heart failure: where we are, where we are going. Internal and Emergency Medicine, 2011, 6, 63-68.	1.0	23
111	Natriuretic peptide in heart failure: where we are, where we are going. Answer to the letter. Internal and Emergency Medicine, 2011, 6, 383-383.	1.0	1
112	Biomarkers in kidney and heart disease. Nephrology Dialysis Transplantation, 2011, 26, 62-74.	0.4	46
113	Clinical Impact of Renal Dysfunction in Heart Failure. Reviews in Cardiovascular Medicine, 2011, 12, 186-199.	0.5	9
114	Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure. Vascular Health and Risk Management, 2010, 6, 411.	1.0	121
115	Definition and classification of Cardio-Renal Syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrology Dialysis Transplantation, 2010, 25, 1416-1420.	0.4	118
116	Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrology Dialysis Transplantation, 2010, 25, 1406-1416.	0.4	188
117	Heart Failure: Pathophysiology and Clinical Picture. Contributions To Nephrology, 2010, 164, 1-10.	1.1	14
118	Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. The Cochrane Library, 2010, , CD007613.	1.5	50
119	Left ventricular remodelling and systolic function measurement with 64 multi-slice computed tomography versus second harmonic echocardiography in patients with coronary artery disease: A double blind study. European Journal of Radiology, 2010, 73, 82-88.	1.2	22
120	Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. European Heart Journal, 2010, 31, 703-711.	1.0	797
121	Osteoprotegerin and B-type natriuretic peptide in acute coronary syndromes with preserved systolic function: Relation to coronary artery disease extension. International Journal of Cardiology, 2009, 137, 295-298.	0.8	6
122	Î²-Erythropoietin Effects on Ventricular Remodeling, Left and Right Systolic Function, Pulmonary Pressure, and Hospitalizations in Patients Affected With Heart Failure and Anemia. Journal of Cardiovascular Pharmacology, 2009, 53, 462-467.	0.8	21
123	Osteoprotegerin and B-type natriuretic peptide in non-ST elevation acute coronary syndromes: Relation to coronary artery narrowing and plaques number. Clinica Chimica Acta, 2008, 391, 74-79.	0.5	21
124	Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm: Comparison with high cardiovascular risk population. Vascular Health and Risk Management, 2008, Volume 4, 877-883.	1.0	46
125	Natriuretic Peptides in Coronary Disease With Non-ST Elevation: New Tools Ready for Clinical Application?. Recent Patents on Cardiovascular Drug Discovery, 2007, 2, 1-4.	1.5	1
126	Effects of Î²-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. American Heart Journal, 2007, 154, 645.e9-645.e15.	1.2	126

#	Article	IF	Citations
127	Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. American Heart Journal, 2006, 152, 1096.e9-1096.e15.	1.2	150
128	Rise and fall of B-type natriuretic peptide levels in patients with coronary artery disease and normal left ventricular function after cardiac revascularization. Coronary Artery Disease, 2006, 17, 419-423.	0.3	7
129	Brain Natriuretic Peptide and Other Risk Markers for Outcome Assessment in Patients With Nonâ€“ST-Elevation Coronary Syndromes and Preserved Systolic Function. American Journal of Cardiology, 2006, 98, 1322-1328.	0.7	27
130	H pyloriinfection and systemic antibodies to CagA and heat shock protein 60 in patients with coronary heart disease. World Journal of Gastroenterology, 2006, 12, 7815.	1.4	37
131	Left Ventricular Diastolic Function Improvement by Carvedilol Therapy in Advanced Heart Failure. Journal of Cardiovascular Pharmacology, 2005, 45, 563-568.	0.8	31
132	Relation of Plasma Brain Natriuretic Peptide Levels in Nonâ€“ST-Elevation Coronary Disease and Preserved Systolic Function to Number of Narrowed Coronary Arteries. American Journal of Cardiology, 2005, 96, 1705-1710.	0.7	29
133	Left ventricular hypertrophy differences in male professional runners and in young patients suffering from mild hypertension. Blood Pressure, 2004, 13, 14-19.	0.7	1
134	Brain natriuretic peptide levels during cardiac reperfusion: comparison between percutaneous coronary angioplasty and aorto-coronaric bypass. Clinica Chimica Acta, 2004, 342, 87-92.	0.5	12
135	Effects of carvedilol therapy on restrictive diastolic filling pattern in chronic heart failure. American Heart Journal, 2004, 147, 73-79.	1.2	18
136	Transmitral and pulmonary venous flow study in elite male runners and young adults. International Journal of Cardiology, 2002, 84, 47-51.	0.8	13